eISSN: 1731-2515
ISSN: 0209-1712
Anestezjologia Intensywna Terapia
Bieżący numer Archiwum O czasopiśmie Rada naukowa Recenzenci Bazy indeksacyjne Prenumerata Kontakt Zasady publikacji prac
Panel Redakcyjny
Zgłaszanie i recenzowanie prac online
Wyszukiwanie
4/2021
vol. 53
 
Poleć ten artykuł:
Wyślij znajomemu
Udostępnij:
streszczenie artykułu:
List do Redakcji

Is the efficacy of remdesivir so different from that of lopinavir–ritonavir in severe COVID-19? The answer by real time-PCR: a narrative review

Tiago Isidoro Duarte
1
,
Cesar Vieira
1
,
Carlos Pimentel
1
,
Mariana Cascão
2
,
Marta Torre
2
,
Joaquim Santos-Lima
2
,
Tânia Sequeira
1
,
Nuno Germano
1
,
Rita Corte-Real
3
,
Luís Bento
2

  1. Polyvalent Intensive Care Unit, Hospital de Curry Cabral, Lisbon, Portugal
  2. Medical Emergency Unit, Hospital de São José, Lisbon, Portugal
  3. Department of Clinical Patology, Hospital de Curry Cabral, Lisbon, Portugal
Anestezjologia Intensywna Terapia 2021; 53, 4: 363–365
Data publikacji online: 2021/12/22
Pełna treść artykułu Pobierz cytowanie
 


This letter discusses the efficacy of current antiviral therapy used in severe COVID-19 infection. Since the first severe cases were documented, several antiviral options have been studied as adjuncts to standard supportive care [1, 2]. Firstly, the combination of lopinavir–ritonavir resurrected from SARS and MERS outbreaks and soon abandoned after the publication of several trials like the randomized controlled trial RECOVERY, which concluded that it was not associated with reductions in 28-day mortality, duration of hospital stay, or risk of progression to invasive mechanical ventilation or death [3]. Remdesivir is currently the only antiviral agent approved for the treatment of COVID-19. It is recommended for use in hospitalized patients who require supplemental oxygen. However, it is not routinely recommended for patients who require mechanical ventilation due to the lack of data showing any benefit at this advanced stage of the disease [4–6].
Termedia
O Wydawnictwie Oferty Newsletter Kontakt Praca
Polityka prywatności Polityka reklamowa Napisz do nas Nota prawna Regulamin
Na skróty
Czasopisma Aktualności Książki eBooki Konferencje i webinary
Serwisy
KONGRES TOP MEDICAL TRENDS Koronawirus Zalecenia i rekomendacje Lekarz POZ Kurier Medyczny Dermatologia Diabetologia e-Praktyka Leczenia Ran Ginekologia Neurologia Onkologia Pulmonologia Reumatologia Menedżer Zdrowia Warto wiedzieć
e-Akademia
e-Akademia Raka Płuca e-Akademia MAFLD e-Akademia Zaburzeń Mikrobioty e-Akademia POChP e-Akademia Chorób Naczyń e-Akademia Chorób Cywilizacyjnych Akademia Zapalenia typu 2 Akademia AZScience
© 2024 Termedia Sp. z o.o.
Developed by Bentus.